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Influenza A(H3N2) virus rapidly evolves to evade human immune responses, resulting in changes in the antigenicity of hemagglutinin (HA). Therefore, continuous genetic and antigenic analyses of A(H3N2) virus are necessary to detect antigenic mutants as quickly as possible.
Methods
We determined the HA sequences of A(H3N2) viruses detected in Yokohama, Japan during the 2016‒2017 and 2017‒2018 influenza seasons to identify amino acid substitutions and the loss or gain of potential N-glycosylation sites in HA, both of which potentially affect the antigenicity of HA. We also examined the antigenicity of isolates using ferret antisera obtained from experimentally infected ferrets.
Results
Influenza A(H3N2) viruses belonging to six clades (clades 3C.2A1, 3C.2A1a, 3C.2A1b, 3C.2A2, 3C.2A3, and 3C.2A4) were detected during the 2016‒2017 influenza season, whereas viruses belonging to two clades (clades 3C.2A1b, and 3C.2A2) dominated during the 2017‒2018 influenza season. The isolates in clades 3C.2A1a and 3C.2A3 lost one N-linked glycosylation site in HA relative to other clades. Antigenic analysis revealed antigenic differences among clades, especially clade 3C.2A2 and 3C.2A4 viruses, which showed distinct antigenic differences from each other and from other clades in the antigenic map.
Conclusion




Influenza A(H3N2) virus has continued to infect humans since its emergence as a pandemic virus in 1968, resulting in considerable economic burden, hospitalizations, and deaths  ADDIN EN.CITE []. After half a century of circulating in humans, A(H3N2) virus has accumulated numerous amino acid substitutions in its hemagglutinin (HA) to escape from human antibodies against this protein. Mouse monoclonal antibodies identified five major antigenic sites, A through E, on HA  ADDIN EN.CITE [, ] and amino acid substitutions at these major antigenic sites are associated with antigenic drift. Based on the antigenicity of HA, A(H3N2) viruses form antigenic clusters  ADDIN EN.CITE []. Seven positions—145 at antigenic site A and 155, 156, 158, 159, 189, and 193 at antigenic site B—are mainly responsible for antigenic cluster transitions  ADDIN EN.CITE []. In addition, modification of HA with N-linked glycans also affects the antigenicity of HA via steric hindrance at these antigenic sites  ADDIN EN.CITE [, ].




Cells. AX4 cells and MDCK-SIAT1 cells [Madin-Darby canine kidney (MDCK) cells, which express higher amounts of 6-linked sialic acids on their cell surface via exogenous expression of human β-galactoside α2,6-sialyltransferase I (ST6Gal I or SIAT1)]  ADDIN EN.CITE [, ] were maintained in Eagle’s minimal essential medium (MEM) containing 10% fetal calf serum (FCS) and Dulbecco’s modified eagle medium (DMEM) containing 5% fetal calf serum and 1 mg/mL G418 sulfate (ThermoFisher Scientific), respectively. Both cell lines were incubated at 37 °C under 5% CO2. 

Viruses. A(H3N2) viruses A/Gunma/140/2017, A/Kagoshima/74146/2017, A/Osaka/163/2017, A/Shimane/112/2017, A/Aichi/343/2017, and A/Okinawa/64/2017 were obtained from Gunma Prefectural Institute of Public Health and Environmental Sciences, Kagoshima Prefectural Institute for Environmental Research and Public Health, Osaka Institute of Public Health, Shimane Prefectural Institute of Public Health and Environment Science, Aichi Prefectural Institute of Public Health, and Okinawa Prefectural Institute of Health and Environment, respectively.

Virus isolation. Clinical specimens were collected in sentinel clinics and hospitals as part of the National Epidemiological Surveillance of Infectious Diseases in Japan. These specimens were tested by reverse transcription (RT)-quantitative PCR (RT-qPCR) targeting H3-HA gene  ADDIN EN.CITE [] and virus isolation was achieved by using AX4 cells.

Sequence analysis. Viral RNA was extracted from the isolated viruses by using an RNeasy Mini Kit (QIAGEN). The viral RNA was subjected to one step RT-PCR to amplify the HA gene by PCR using the AccessQuick RT-PCR system (Promega) as follows: after 45 min of cDNA synthesis at 48 °C and 2 min of denaturation at 94 °C, samples were subjected to 40 cycles of amplification, consisting of 1 min at 94 °C, 90 s at 55 °C, and 2 min at 68 °C, with a final additional extension step at 68 °C for 10 min. The PCR products were purified with a QIAquick PCR Purification Kit (QIAGEN) and then sequenced using a BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems) on an ABI 3500 sequencer (Applied Biosystems).

Phylogenetic analysis. The phylogenetic tree was constructed by using the Neighbor-Joining method with Kimura distances and the bootstrap procedure (n=1000) using ClustalW 2.1 on the DDBJ (DNA Data Bank of Japan) website (http://clustalw.ddbj.nig.ac.jp/) and was visualized by using the MEGA 7.0.26 software. A/Perth/16/2009 is defined as an outgroup. HA sequences of reference isolates were obtained from the Global Initiative on Sharing Avian Influenza Data (GISAID) database. The sequencing data set used in this study is available upon request.

Three-dimensional mapping. Amino acid positions were plotted on an HA trimer of A/Victoria/361/2011 (PDB ID code 4O5N) by using the PyMOL molecular graphics system. The N-glycans on the HA trimer were added to the N-linked glycosylation sites by using the GlyProt web server (http://www.glycosciences.de/modeling/glyprot/php/main.php) and visualized by using the molecular graphics system PyMOL.

Ferret antisera. The ferret antisera were produced at Japan SLC Inc. with the approval of Japan’s Institutional Animal Care and Use Committee of the National Institute of Infectious Diseases. Adult male ferrets (Japan SLC Inc.) that were serologically negative for influenza viruses were infected with the indicated A(H3N2) virus via the respiratory tract as a viral vapor generated by a nebulizer. At two weeks after infection, whole blood collected from the ferrets under anesthesia was coagulated. The serum supernatants after centrifugation were collected as the antiserum. The serum samples were treated with receptor destroying enzyme, RDE II (SEIKEN), according to manufacturer’s instructions prior to use in the virus micro-neutralization assay.

Antigenic analysis. For antigenic analysis, a focus reduction assay, an in vitro virus micro-neutralization assay based on the concept of plaque reduction, was conducted. Briefly, after 50 l of 2-fold serial dilutions of the ferret antisera in DMEM containing 200 nM oseltamivir was added to a monolayer of MDCK-SIAT1 cells in a 96-well plate, 1,000 focus-forming units of the indicated virus (50 µl) was added to each well. After a 1-h incubation, 1.6% Avicel RC-581 (FMC BioPolymer) in DMEM was overlaid. Oseltamivir was used to prevent receptor binding via NA, and trypsin was not added to avoid virus multiplication. At 18‒20 h after infection, the cells were stained with mouse anti-nucleoprotein (NP) monoclonal antibodies (MAB8257 & MAB8258, Millipore), followed by an anti-mouse IgG antibody conjugated with horseradish peroxidase. NP-positive cells were visualized with KPL TrueBlueTM substrate (Kirkegaard & Perry Laboratories) to count foci. The reciprocal number of the minimum dilution of sera needed to achieve 50% focus reduction was used as the neutralization titer.





A(H3N2) viruses circulating in Yokohama. During the 2016‒2017 and 2017‒2018 influenza seasons, we detected 227 A(H3N2) viruses from clinical samples collected in Yokohama, Japan: 225 viruses were isolated using AX4 cells and two were positive by RT-qPCR (Figure 1). The HA sequences were determined by Sanger sequencing, and HA genetic clades were determined based on reference isolates available through GISAID. To draw the phylogenetic tree using the neighbor-joining method with Kimura distances, we selected several isolates as representative of each clade. We found that A(H3N2) viruses isolated during the 2016‒2017 and 2017‒2018 influenza seasons in Yokohama could be classified into 6 clades: 3C.2A1, 3C.2A1a, 3C.2A1b, 3C.2A2, 3C.2A3, and 3C.2A4 (Figure 1 and Figure 2A), based on the WHO designations. We considered one case to be a co-infection with A(H3N2) viruses of two different clades because we detected HA sequences of clades 3C.2A1a and 3C.2A4. Isolates of all 6 clades were detected during the 2016‒2017 influenza season, whereas several isolates of clades 3C.2A1b, 3C.2A2, and 3C.2A3 and no isolates of clades 3C.2A1, 3C.2A1a, and 3C.2A4 were detected during the 2017‒2018 influenza season (Figure 1). These results demonstrate that several different clades of A(H3N2) viruses simultaneously caused influenza in the city and the diversity of the circulating clades differed between the 2016‒2017 and the 2017‒2018 influenza seasons; vaccine strain for A(H3N2) virus was identical between two seasons, A/Hong Kong/4801/2014.

Changes in the N-linked glycosylation sites on H3-HA. We next focused on the putative N-linked glycosylation sites on the H3-HA molecule because gradual accumulation of putative N-linked glycosylation sites has been linked to escape from human antibody pressure  ADDIN EN.CITE []. On a single HA molecule of A/Perth/16/2009, we found 11 putative N-linked glycosylation sites (Figure 2B). Clade 3B or 3C.1 viruses acquired one or two putative N-linked glycosylation sites at positions 144‒146 (NSS) or 45‒47 (NSS) and 144‒146 (NSS) due to the S45N or S144N substitution. Among the clade 3C.2A viruses, the N144S substitution and the K160T substitution abolished and created the putative N-linked glycosylation site at positions 144‒146 and 158‒160 (NYT), respectively. The N-linked glycosylation sites of clade 3C.2A viruses were conserved among isolates of clades 3C.2A1b, 3C.2A2, and 3C.2A4, whereas some viruses in clade 3C.2A1b possessed the T135K or T135N substitution, causing the loss of the glycosylation site at positions 133‒135 (NGK or NGN) and the gain of the glycosylation site at positions 135‒137 (NSS). Several isolates of clade 3C.2A1a lost two putative N-linked glycosylation sites at positions 122‒124 (NES) and 133-135 (NGT) due to the N122D and T135K substitutions. Isolates of clade 3C.2A3 lost a putative N-linked glycosylation site at position 135 (NGT) as a result of the T135K substitution. Thus, viruses with HA that possessed different N-linked glycosylation sites, which possibly affected antigenicity, cocirculated.

Antigenicity analysis. Since the phylogenetic tree revealed that A(H3N2) viruses that were distinct in terms of their HA sequence and number of HA glycosylation sites co-circulated in Yokohama during the 2016‒2017 and 2017‒2018 influenza seasons, we examined the antigenicity of viruses from different clades using sera obtained from infected ferrets. We prepared ferret antisera by infecting ferrets with each of five A(H3N2) isolates: A/Hong Kong/7127/2014 (clade 3C.2A), which is antigenically similar to A/Hong Kong/4801/2014 (clade 3C.2A), the vaccine seed virus for the Northern hemisphere 2016‒2017 and 2017‒2018 influenza seasons; A/Singapore/INFIMH-16-0019/2016 (clade 3C.2A1), the vaccine seed virus for the 2018 Southern and 2018‒2019 Northern hemisphere influenza season; A/Osaka/163/2017 as a representative of clade 3C.2A1b; A/Shimane/112/2017, as a representative of clade 3C.2A2; and A/Yokohama/138/2017 as a representative of clade 3C.2A4 (Figure 2A). For the antigenicity analysis, we selected 16 isolates (Table 2). We compared the HA sequence of the selected isolates with that of A/Hong Kong/7127/2014 (Hong Kong/7127, clade 3C.2A) at antigenic sites A through E  ADDIN EN.CITE [, ] and mapped them onto the H3-HA molecule (Figure 3 and Table 1). All six isolates possessed one or two substitutions at antigenic site D. An amino acid substitution at antigenic site A or E was found in five or four isolates, whereas that at antigenic site B or C was found in one or two isolates. A/Kagoshima/74146/2017, A/Yokohama/199/2017, A/Yokohama/14/2018, A/Yokohama/148/2017, A/Aichi/343/2017, and A/Okinawa/64/2017 possessed identical HA antigenic sites to those of other viruses of the same clade. A/Yokohama/181/2017 and A/Yokohama/1/2018 possessed three additional substitutions (E62G, T135K, and R142G) at antigenic sites E, A, and A, respectively. A/Yokohama/145/2017 possessed one additional substitution (T135N) at antigenic site A. Both the T135K and T135N mutations abolished the potential N-glycosylation site at positions 133–135 and T135N mutation generated the glycosylation site at positions 135‒137. All of the tested viruses were isolated and passaged using MDCK cells or derivative AX4  ADDIN EN.CITE [] or MDCK-SIAT1 cells  ADDIN EN.CITE []. 
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Figure 1. Number of influenza cases in Yokohama during the 2016‒2017 and 2016‒2018 influenza seasons. The number of cases affected by influenza A(H3N2) viruses is summarized based on the HA clades, which were assigned according to WHO reports.

Figure 2. Phylogenic tree of the HA sequences of isolates detected in this study and N-linked glycosylation on the H3-HA molecule. (A) Phylogenic tree of the HA sequence. The evolutionary history was inferred using the Neighbor-Joining method with Kimura distances. The viruses isolated in this study are indicated by black circles. The clade of the reference isolates, which are available in the GISAID database, is indicated in parentheses. Amino acid substitutions delineating major branches are shown. Amino acid changes involved in loss or gain of N-glycosylation are shown in green or red, respectively. The isolates used for antigenic analysis are shown in orange. A/Perth/16/2009 is defined as an outgroup. (B) Alteration of N-linked glycosylation on H3-HA. N-linked glycans present on all of the HAs on the HA trimer of A/Victoria/361/2011 (PDB ID code 4O5N) were added to the N-linked glycosylation sites in the crystal structure by using the GlyProt web server and visualized by using the molecular graphics system PyMOL. Consensus sequences of clades 3B, 3C.1, and 3C.2A and representative isolates of each clade were used. Newly emerged N-linked glycans at N45, N144, and N158 are shown in red and the lost glycans at N122 and N133 are shown in light pink. Other N-linked glycans are shown in cyan. The receptor binding site is shown in yellow.

Figure 3. Amino acid substitution sites mapped onto the H3-HA molecule. Amino acid substitutions at the antigenic sites of H3-HA derived from A/Singapore/INFIMH-16-0019/2016, A/Gunma/140/2017, A/Osaka/163/2017, A/Shimane/112/2017, A/Yokohama/150/2017, or A/Yokohama/138/2017 compared with A/Hong Kong/7127/2014 (Clade 3C.2A) were mapped onto the HA trimer and are indicated by purple, orange, red, green, blue, and brown, respectively, with the antigenic sites in parentheses. High-mannose type N-linked glycans (shown in cyan) on the HA trimer of A/Victoria/361/2011 (PDB ID code 4O5N) have been added. Amino acid substitutions involved in the loss of an N-glycosylation site are underlined. The receptor binding site is shown in yellow.

Figure 4. An antigenic 3D map of A(H3N2) viruses. An antigenic 3D map was generated from the neutralization data in Table 2. Viruses are represented as circles, antisera as squares. Strains are colored based on the clades. The grid indicates 1 unit of antigenic distance, a 2-fold dilution in neutralization titer.
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